Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Mangoceuticals, Inc. is a smaller reporting company and emerging growth company focused on scaling its operations and marketing its products. The filing highlights significant risks including a limited operating history, the need for additional funding, and reliance on third-party compounding pharmacies for products not approved by the FDA.
CDT Equity Inc. reported a net loss of $13.3 million for the nine months ended September 30, 2026, compared to $17.9 million in the prior year. The company significantly expanded its balance sheet through a $153.5 million equity method investment, resulting in total assets increasing from $5.7 million to $158.7 million.
BluSky AI Inc. reported a net loss of $1,476,476 for the nine months ended September 30, 2026, compared to a net loss of $4,014,763 in the prior year period. The company remains in a stockholders' deficit position of $787,655, though it successfully raised $1,910,966 through common stock issuances during the period.
Longduoduo Co Ltd reported a significant revenue decline to $17,595 for the quarter ended September 30, 2026, compared to $658,764 in the prior year, primarily due to a sharp drop in commission revenue. The company realized a net loss of $474,167 for the period and underwent a corporate restructuring involving the deregistration of its Hong Kong subsidiary.
SDR Drone, Inc. reported a net loss of $598,438 for the nine months ended September 30, 2026, compared to a loss of $760,649 in the prior year period. The company remains in a development stage with zero revenue and a stockholders' deficit of $243,944, primarily driven by professional fees and non-cash expenses related to debt amortization and derivative liabilities.
For the nine months ended September 30, 2026, ConnectM Technology Solutions reported revenues of $26.35 million, an increase from $24.31 million in the prior year. The company recorded a net loss attributable to stockholders of $2.32 million, significantly improved from a $12.18 million loss in 2025, primarily due to a $19.05 million gain on the disposal of discontinued operations.
Host Digital Inc. reported a net loss of $11.45 million for the eight months ended September 30, 2026, following a reverse acquisition and public offering in September 2026. The company generated $1.48 million in net sales during the period, while significantly expanding its balance sheet to $108.2 million in total assets, primarily through intangible assets and right-of-use assets.
Picard Medical, Inc. is a newly public medical device company focused on total artificial heart therapy, reporting 2,661,574 shares outstanding as of November 12, 2026. The filing highlights significant risks including customer concentration, reliance on single-source suppliers, and an explanatory paragraph from its auditors regarding its ability to continue as a going concern.
Cyabra, Inc. reported revenues of $5.27 million for the nine months ended September 30, 2026, compared to $4.08 million in the prior year period. The company experienced a significant net loss of $16.8 million, driven by increased research and development and general administrative expenses following a business combination and PIPE financing.
NovelStem International Corp. reported a net loss of $225,105 for the nine months ended September 30, 2026, compared to a net income of $2,469,177 in the prior year period which was driven by one-time debt relief and investment disposal gains. The company continues to operate with a significant shareholders' deficit of $2.1 million and requires additional financing to sustain operations following the liquidation of its primary equity investment, NewStem.
The filing highlights significant volatility in natural gas and helium markets, noting that Henry Hub spot prices fluctuated between $2.54 and $30.72 per MMBtu in early 2026. Renergen faces substantial liquidity risks related to its debt covenants and capital expenditure requirements for Phase 2 expansion, while global helium supply remains constrained with spot prices exceeding $2,000/Mcf due to geopolitical disruptions.
Hydrofarm Holdings Group reported a significant decline in net sales to $14.5 million for the third quarter of 2026 compared to $29.4 million in the prior year, driven by industry oversupply and customer pricing pressures. The company recorded a net loss for the nine-month period of $33.0 million and reported a total stockholders' deficit of $93.9 million, raising concerns about its ability to continue as a going concern.
Traws Pharma reported Q3 2026 financial results and provided clinical updates for its COVID-19 and influenza antiviral programs. The company highlighted positive Phase 2a results for ratutrelvir and plans to engage the FDA on a registration strategy for PAXLOVID-ineligible patients.
Term
Q3 2026
“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases.”
Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma
“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter.”
Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma
Bridger Aerospace Group Holdings Financial Results
Bridger Aerospace reported third quarter 2026 revenue of $56.7 million, a 13% increase compared to the prior year period. The company announced a strategic review of alternatives to refocus on core aerial services and high-margin business lines. Additionally, the company reported a net loss of $1.8 million for the quarter, an improvement from a $13.4 million net loss in Q3 2025.
Toppoint Holdings reported Q3 2026 revenue of $4.5 million and a net loss of $0.09 million, a significant improvement from the $4.15 million loss in the prior-year period. The company also announced a one-for-five reverse stock split effective November 23, 2026, following a trading halt by NYSE American due to low share price.
AMC Robotics reported Q3 2026 revenue of $0.97 million, a 3.1% sequential increase driven by product sales growth. The company is prioritizing its Kyro quadruped robotic platform for security and inspection markets while remaining on track to commission its Vietnam manufacturing facility by year-end 2026.
Term
Q3 2026
“During the quarter, we sharpened our strategic focus on advancing Kyro, our quadruped robotic platform, toward commercialization, prioritizing opportunities in security, surveillance and inspection markets.”
Sean Da, Chairman of the Board and CEO of AMC Robotics
“The appointment of Dr. Ang Li as Chief Technology Officer further strengthens our ability to accelerate product development and bring more advanced autonomous capabilities to market, while continued progress at our Vietnam manufacturing facility keeps us on track towards initial trial production in early 2027.”
Sean Da, Chairman of the Board and CEO of AMC Robotics
Sadot Group Inc. reported a significant turnaround for the nine months ended September 30, 2026, with a net income of $32.2 million compared to a net loss of $14.2 million in the prior year, primarily driven by a $42.4 million gain on deconsolidation. Despite this, the company experienced a net loss of $3.0 million for the third quarter of 2026 as commodity sales fell sharply compared to the prior year's nine-month volume.
NRX Pharmaceuticals reported a net loss of $20.1 million for the nine months ended September 30, 2026, an improvement from the $29.0 million loss in the prior year period. The company significantly increased its cash position to $19.8 million through various equity offerings, while net patient service revenue grew to $3.3 million.
BrainStorm Cell Therapeutics reported a net loss of $7.7 million for the nine months ended September 30, 2026, compared to $7.9 million in the prior year period. The company faces a significant stockholders' deficit of $12.3 million and maintains a very low cash position of $163 thousand, relying on private placements and short-term loans to fund operations.
MediaCo Holding Inc. reported a net loss of $9.3 million for the third quarter of 2026, compared to a $17.9 million loss in the prior year period. Net revenues decreased to $28.6 million from $35.4 million year-over-year, while the company's total liabilities increased slightly to $249.1 million as of September 30, 2026.
Swarmer, Inc. reported a significant increase in net loss to $21.1 million for the nine months ended September 30, 2026, compared to $5.7 million in the prior year, primarily driven by a surge in operating expenses following its initial public offering. Despite the loss, the company strengthened its liquidity position, ending the period with $37.3 million in cash and cash equivalents.
Okmin Resources reported a net loss of $122,493 for the quarter ended September 30, 2026, compared to a loss of $73,430 in the prior year period. The company's financial position remains strained with a working capital deficit of $776,920 and a significant impairment charge of $53,872 taken on its oil and gas properties during the quarter.
Iron Dome Acquisition I Corp. reported net income of $1,087,694 for the quarter ended September 30, 2026, primarily driven by $1,408,474 in interest income from its Trust Account. As a shell company, its primary activities involved completing its initial public offering and managing $159,850,245 in cash held in trust for a future business combination.
AgEagle Aerial Systems reported a significant decline in nine-month revenue from $9.82 million in 2025 to $5.97 million in 2026, alongside a net loss of $21.78 million. The company's cash position decreased from $29.86 million at year-end 2025 to $10.16 million as of September 30, 2026, driven by increased operating expenses and unrealized losses on investments.
Target Group Inc. reported a significant revenue increase to $4.27 million for the nine months ended September 30, 2026, compared to $3.15 million in the prior year. Despite higher gross profits, the company realized a net loss of $958,449 for the period, contributing to a total stockholders' deficiency of $8.83 million.
KRAKacquisition Corp reported a net loss of $3,020,297 for the nine months ended September 30, 2026, primarily driven by $11.36 million in general and administrative expenses. As a blank check company, it successfully completed its Initial Public Offering in January 2026, resulting in $352,953,916 held in a Trust Account for a future business combination.
For the nine months ended September 30, 2026, 20/20 Biolabs, Inc. reported a net loss of $5.06 million on revenues of $1.46 million, compared to a net loss of $2.43 million on revenues of $1.51 million in the prior year period. The company experienced a significant increase in operating expenses, primarily driven by sales, general, and administrative costs, and underwent a major capital restructuring involving the conversion of multiple preferred stock series into common stock.
Creative Media & Community Trust Corp reported a net loss attributable to common stockholders of $64.8 million for the nine months ended September 30, 2026, compared to a $43.9 million loss in the prior year period. The company experienced significant non-cash charges, including a $7.97 million real estate impairment and $22.4 million in preferred stock redemptions, while total revenues slightly decreased to $86.5 million.
Marker Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, highlighting continued progress in its clinical-stage cell therapy pipeline. The company maintained a net loss as it invests in R&D, with sufficient cash reserves to support operations into the following year.
For the nine months ended September 30, 2026, Beacon Topco reported a net loss of $22.2 million, a significant reduction from the $55.4 million loss in the prior year period. The company maintained a cash position of $49.2 million and plans to rename itself Clywedog Therapeutics Holdings, Inc. following a pending merger transaction.